7 research outputs found
HHV-8 seroprevalence: a global view
BACKGROUND: Human herpes virus 8 (HHV-8) is the underlying infectious cause of Kaposi sarcoma (KS) and other proliferative diseases; that is, primary effusion lymphoma and multicentric Castleman disease. In regions with high HHV-8 seroprevalence in the general population, KS accounts for a major burden of disease. Outside these endemic regions, HHV-8 prevalence is high in men who have sex with men (MSM) and in migrants from endemic regions. We aim to conduct a systematic literature review and meta-analysis in order 1) to define the global distribution of HHV-8 seroprevalence (primary objective) and 2) to identify risk factors for HHV-8 infection, with a focus on HIV status (secondary objective).METHODS/DESIGN:We will include observational studies reporting data on seroprevalence of HHV-8 in children and/or adults from any region in the world. Case reports and case series as well as any studies with fewer than 50 participants will be excluded. We will search MEDLINE, EMBASE, and relevant conference proceedings without language restriction. Two reviewers will independently screen the identified studies and extract data on study characteristics and quality, study population, risk factors, and reported outcomes, using a standardized form. For the primary objective we will pool the data using a fully bayesian approach for meta-analysis, with random effects at the study level. For the secondary objective (association of HIV and HHV-8) we aim to pool odds ratios for the association of HIV and HHV-8 using a fully bayesian approach for meta-analysis, with random effects at the study level. Sub-group analyses and meta-regression analyses will be used to explore sources of heterogeneity, including factors such as geographical region, calendar years of recruitment, age, gender, ethnicity, socioeconomic status, different risk groups for sexually and parenterally transmitted infections (MSM, sex workers, hemophiliacs, intravenous drug users), comorbidities such as organ transplantation and malaria, test(s) used to measure HHV-8 infection, study design, and study quality.DISCUSSION:Using the proposed systematic review and meta-analysis, we aim to better define the global seroprevalence of HHV-8 and its associated risk factors. This will improve the current understanding of HHV-8 epidemiology, and could suggest measures to prevent HHV-8 infection and to reduce its associated cancer burden
Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies.
BACKGROUND: Kaposi sarcoma (KS) remains a frequent cancer in human immunodeficiency virus (HIV)-positive patients starting combination antiretroviral therapy (cART). We examined incidence rates and risk factors for developing KS in different periods after starting cART in patients from European observational HIV cohorts. METHODS: We included HIV-positive adults starting cART after 1 January 1996. We analyzed incidence rates and risk factors for developing KS up to 90 and 180 days and 1, 2, 5, and 8 years after cART start and fitted univariable and multivariable Cox regression models. RESULTS: We included 109 461 patients from 21 prospective clinical cohorts in Europe with 916 incident KS cases. The incidence rate per 100 000 person-years was highest 6 months after starting cART, at 953 (95% confidence interval, 866-1048), declining to 82 (68-100) after 5-8 years. In multivariable analyses adjusted for exposure group, origin, age, type of first-line regimen, and calendar year, low current CD4 cell counts increased the risk of developing KS throughout all observation periods after cART initiation. Lack of viral control was not associated with the hazard of developing KS in the first year after cART initiation, but was over time since starting cART increasingly positively associated (P < .001 for interaction). CONCLUSION: In patients initiating cART, both incidence and risk factors for KS change with time since starting cART. Whereas soon after starting cART low CD4 cell count is the dominant risk factor, detectable HIV-1 RNA viral load becomes an increasingly important risk factor in patients who started cART several years earlier, independently of immunodeficiency
HIV and human herpesvirus 8 co-infection across the globe: Systematic review and meta-analysis.
HIV-infection is an important risk factor for developing Kaposi sarcoma (KS), but it is unclear whether HIV-positive persons are also at increased risk of co-infection with human herpesvirus 8 (HHV-8), the infectious cause of KS. We systematically searched literature up to December 2012 and included studies reporting HHV-8 seroprevalence for HIV-positive and HIV-negative persons. We used random-effects meta-analysis to combine odds ratios (ORs) of the association between HIV and HHV-8 seropositivity and conducted random-effects meta-regression to identify sources of heterogeneity. We included 93 studies with 58,357 participants from 32 countries in sub-Saharan Africa, North and South America, Europe, Asia, and Australia. Overall, HIV-positive persons were more likely to be HHV-8 seropositive than HIV-negative persons (OR 1.99, 95% confidence interval [CI] 1.70-2.34) with considerable heterogeneity among studies (I(2) 84%). The association was strongest in men who have sex with men (MSM, OR 3.95, 95% CI 2.92-5.35), patients with hemophilia (OR 3.11, 95% CI 1.19-8.11), and children (OR 2.45, 95% CI 1.58-3.81), but weaker in heterosexuals who engage in low-risk (OR 1.42, 95% CI 1.16-1.74) or high-risk sexual behavior (OR 1.66, 95% CI 1.27-2.17), persons who inject drugs (OR 1.66, 95% CI 1.28-2.14), and pregnant women (OR 1.68, 95% CI 1.15-2.47), p value for interaction <0.001. In conclusion, HIV-infection was associated with an increased HHV-8 seroprevalence in all population groups examined. A better understanding of HHV-8 transmission in different age and behavioral groups is needed to develop strategies to prevent HHV-8 transmission
Incidence Rate of Kaposi Sarcoma in HIV-Infected Patients on Antiretroviral Therapy in Southern Africa: A Prospective Multicohort Study.
BACKGROUND
The risk of Kaposi sarcoma (KS) among HIV-infected persons on antiretroviral therapy (ART) is not well defined in resource-limited settings. We studied KS incidence rates and associated risk factors in children and adults on ART in Southern Africa.
METHODS
We included patient data of 6 ART programs in Botswana, South Africa, Zambia, and Zimbabwe. We estimated KS incidence rates in patients on ART measuring time from 30 days after ART initiation to KS diagnosis, last follow-up visit, or death. We assessed risk factors (age, sex, calendar year, WHO stage, tuberculosis, and CD4 counts) using Cox models.
FINDINGS
We analyzed data from 173,245 patients (61% female, 8% children aged 2 years after ART initiation]. Male sex [adjusted hazard ratio (HR): 1.34; 95% CI: 1.12 to 1.61], low current CD4 counts (≥500 versus <50 cells/μL, adjusted HR: 0.36; 95% CI: 0.23 to 0.55), and age (5-9 years versus 30-39 years, adjusted HR: 0.20; 95% CI: 0.05 to 0.79) were relevant risk factors for developing KS.
INTERPRETATION
Despite ART, KS risk in HIV-infected persons in Southern Africa remains high. Early HIV testing and maintaining high CD4 counts is needed to further reduce KS-related morbidity and mortality
Changing incidence and risk factors for Kaposi sarcoma by time since starting antiretroviral therapy: Collaborative analysis of 21 European cohort studies.
BACKGROUND
Kaposi sarcoma (KS) remains a frequent cancer in HIV-positive patients initiating combination antiretroviral therapy (cART). We examined incidence rates and risk factors for developing KS in different periods since starting cART in patients from European observational HIV-cohorts.
METHODS
We included HIV-positive adults starting cART after 01/01/1996. We analyzed incidence rates and risk factors for developing KS up to 90, 180 days and one, two, five, and eight years after cART start and fitted univariable and multivariable Cox regression models.
RESULTS
We included 109,461 patients from 21 prospective clinical cohorts in Europe with 916 incident KS cases. The incidence rate per 100,000 person-years was highest six months after starting cART (953, 95% CI 866-1,048) and declined to 82 (95% CI 68-100) after five to eight years. Using multivariable analyses adjusted for exposure group, origin, age, type of first-line regimen and calendar year, low current CD4 cell counts increased the risk of developing KS throughout all observation periods after starting cART. Lack of viral control was not associated with the hazard of developing KS in the first year after cART initiation, but was over time since starting cART increasingly positively associated (p<0.001 for interaction).
CONCLUSION
In patients who started cART both incidence and risk factors for KS change with time since starting cART. Whereas early after starting cART low CD4 cell count is the dominant risk factor, detectable HIV-1 RNA viral load becomes an increasingly important risk factor in patients who started cART several years ago, independently of immunodeficiency
Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies
Background. Kaposi sarcoma (KS) remains a frequent cancer in human
immunodeficiency virus (HIV)-positive patients starting combination
antiretroviral therapy (cART). We examined incidence rates and risk
factors for developing KS in different periods after starting cART in
patients from European observational HIV cohorts.
Methods. We included HIV-positive adults starting cART after 1 January
1996. We analyzed incidence rates and risk factors for developing KS up
to 90 and 180 days and 1, 2, 5, and 8 years after cART start and fitted
univariable and ultivariable Cox regression models.
Results. We included 109 461 patients from 21 prospective clinical
cohorts in Europe with 916 incident KS cases. The incidence rate per 100
000 person-years was highest 6 months after starting cART, at 953 (95%
confidence interval, 866-1048), declining to 82 (68-100) after 5-8
years. In multivariable analyses adjusted for exposure group, origin,
age, type of first-line regimen, and calendar year, low current CD4 cell
counts increased the risk of developing KS throughout all observation
periods after cART initiation. Lack of viral control was not associated
with the hazard of developing KS in the first year after cART
initiation, but was over time since starting cART increasingly
positively associated (P<.001 for interaction).
Conclusion. In patients initiating cART, both incidence and risk factors
for KS change with time since starting cART. Whereas soon after starting
cART low CD4 cell count is the dominant risk factor, detectable HIV-1
RNA viral load becomes an increasingly important risk factor in patients
who started cART several years earlier, independently of
immunodeficiency